Movement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year

Market Focus

Aug 27

On August 27, HANSOH PHARMA rose 5.73% in regular trading, trading at 34.12 HKD/share, with turnover of HK$51.35 million.

On the news front, the company released its interim results after market close on August 26. For the first half, HANSOH PHARMA reported revenue of RMB 8.3 billion, up 11.7% year-over-year, while net profit attributable to shareholders surged 35.8% to RMB 4.26 billion. Earnings per share rose to RMB 0.70 from RMB 0.53 in the prior-year period. The strong profit growth was primarily driven by increasing innovative drug revenue, which now accounts for 85.4% of total sales. The oncology segment contributed RMB 5.47 billion, representing approximately 65.9% of revenue. R&D spending reached RMB 1.74 billion, up 20.7%, with over 70 innovative drug clinical trials currently underway. The company also declared an interim dividend of HK$0.285 per share, payable October 29.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1158953188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158953188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158953188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 09:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158953188","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year","media":"Market Focus","content":"<p><p>On August 27, HANSOH PHARMA rose 5.73% in regular trading, trading at 34.12 HKD/share, with turnover of HK$51.35 million.</p><p>On the news front, the company released its interim results after market close on August 26. For the first half, HANSOH PHARMA reported revenue of RMB 8.3 billion, up 11.7% year-over-year, while net profit attributable to shareholders surged 35.8% to RMB 4.26 billion. Earnings per share rose to RMB 0.70 from RMB 0.53 in the prior-year period. The strong profit growth was primarily driven by increasing innovative drug revenue, which now accounts for 85.4% of total sales. The oncology segment contributed RMB 5.47 billion, representing approximately 65.9% of revenue. R&D spending reached RMB 1.74 billion, up 20.7%, with over 70 innovative drug clinical trials currently underway. The company also declared an interim dividend of HK$0.285 per share, payable October 29.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 5.73% in Regular Trading, H1 Net Profit Surges 35.8% Year-over-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 09:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, HANSOH PHARMA rose 5.73% in regular trading, trading at 34.12 HKD/share, with turnover of HK$51.35 million.</p><p>On the news front, the company released its interim results after market close on August 26. For the first half, HANSOH PHARMA reported revenue of RMB 8.3 billion, up 11.7% year-over-year, while net profit attributable to shareholders surged 35.8% to RMB 4.26 billion. Earnings per share rose to RMB 0.70 from RMB 0.53 in the prior-year period. The strong profit growth was primarily driven by increasing innovative drug revenue, which now accounts for 85.4% of total sales. The oncology segment contributed RMB 5.47 billion, representing approximately 65.9% of revenue. R&D spending reached RMB 1.74 billion, up 20.7%, with over 70 innovative drug clinical trials currently underway. The company also declared an interim dividend of HK$0.285 per share, payable October 29.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1158953188","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158953188","pubTimestamp":1787794271,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, HANSOH PHARMA rose 5.73% in regular trading, trading at 34.12 HKD/share, with turnover of HK$51.35 million.On the news front, the company released its interim results after market close...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势提醒|豪森制药常规交易上涨5.73%，上半年净利润同比飙升35.8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 27, HANSOH PHARMA rose 5.73% in regular trading, trading at 34.12 HKD/share, with turnover of HK$51.35 million.On the news front, the company released its interim results after market close on August 26. For the first half, HANSOH PHARMA reported revenue of RMB 8.3 billion, up 11.7% year-over-year, while net profit attributable to shareholders surged 35.8% to RMB 4.26 billion. Earnings per share rose to RMB 0.70 from RMB 0.53 in the prior-year period. The strong profit growth was primarily driven by increasing innovative drug revenue, which now accounts for 85.4% of total sales. The oncology segment contributed RMB 5.47 billion, representing approximately 65.9% of revenue. R&D spending reached RMB 1.74 billion, up 20.7%, with over 70 innovative drug clinical trials currently underway. The company also declared an interim dividend of HK$0.285 per share, payable October 29.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}